Objective To investigate the safety and efficacy of nephron-sparing surgery (NSS)for selective T2 stage renal tumor.Methods The surgical database of 26 patients treated with NSS for clinical T2 stage renal cell carcinomas between March 2010 and May 2013 were collected and analyzed retrospectively.There were 17 males and 9 females,with a mean age of 52 years (39-74 years),mean tumor size of 10.3 cm(7.2-16.5 cm),and mean R.E.N.A.L score of 7.5 (6-10).Patients'demographics,clinical characteristics,oncologic outcomes,renal function were reviewed.Results The renal masses were removed successfully and the surgical margins were negative.There were 21 (80.8％) cases of clear cell carcinoma,4 (15.4％) papillary carcinoma and 1 (3.8％) chromophobe carcinoma.The mean ischemia time was (28.3 ± 12.5) minutes (7 patients were clamp-free).Three patients needed transfusion,one experienced urine fistula and cured by conservative treatment,and one patient's renal function got progressive worsening and required long-term hemodialysis.The average serum creatinine was 121 μ mol/L before and 136 μmol/L after surgery (P =0.06).After a period of 22-47 months' follow-up,no patient had local recurrence or metastasis.Conclusions NSS can be safely performed and provide effective oncologic outcomes for selective patients with clinical T2 stage renal cell carcinomas.R.E.N.A.L nephrometry is an important factor and should be used to evaluate the feasibility of NSS.

Objective: To investigate the influence of routine antagonist and optimization super-long termovulation promotion scheme on clinical outcome of patients with IVF-ET/ICSI and POR. Methods: One hundred and thirty patients with IVF-ET/ICSI and POR were chosen in the period from October 2014 to May 2016 and randomly divided into two groups including control group (65 patients) with routine antagonist scheme and observation group (65 patients) with optimization super-long term scheme for ovulation promotion; and the number and total dose of Gn application, endometrium thickness and P levels in HCG day, the number of ovum retrieved, the incidence of premature LH peak, fertilization rate, quality embryo rate, cycle cancellation rate, implantation rate, clinical pregnancy rate, abortion rate and ectopic pregnancy rate of two groups were compared. Results: The number and total doses of Gn application of observation group were significant higher than those of control group:(12.50 ± 1.78) d vs.(8.16 ± 1.25) d, (4 272.81 ± 547.95) U vs. (1 909.13 ± 341.48) U (P<0.05). The endometrium thickness and P levels in HCG day of observation group were significant lower than those of control group: (12.86 ± 1.39) mm vs. (10.08 ± 1.02) mm, (0.43 ± 0.17) nmol/L vs. (0.60 ± 0.22) nmol/L (P<0.05). There was no significant difference in the number of ovum retrieved, the incidence of premature LH peak and fertilization rate between two groups (P > 0.05). The quality embryo rate and cycle cancellation rate of observation group was significant lower than that of control group (P<0.05). The implantation rate and clinical pregnancy rate of observation group were significant higher than that of control group (P<0.05).There was no significant difference in the abortion rate and ectopic pregnancy rate between two groups (P > 0.05). Conclusions Compared with routine antagonist scheme, optimization super-long termscheme for ovulation promotion in the treatment of patients with IVF-ET/ICSI and POR can efficiently improve the ovulation effects and increase the long-term pregnancy rate, but has the higher overall treatment cost.